DR-70 (fibrinogen-fibrin Degradation Products) As a Prognostic Biomarker in Dogs with Neoplasms

Overview

Journal Vet Q

Specialty Veterinary Medicine

Date 2024 Jul 19

PMID 39028259

Authors

Chiao-Hsu Ke

Chen-Si Lin

Ka-Mei Sio

Chun-Hung Wu

Yuan-Yuan Xia

Jih-Jong Lee

Chin-Hao Hu

Cheng-Chi Liu

Bor-Song Liaw

Chiao-Lei Cheng

Keng-Hsuan Lin

Yu-Shan Wang

Affiliations

Soon will be listed here.

Abstract

Fibrinogen-fibrin degradation products (DR-70) are derived from tumor cells or metastases. Our previous study reported the diagnostic values in dogs with tumors, but no research has yet to be conducted to establish DR-70 as a prognostic marker. Herein, we investigated changes in DR-70 concentrations and disease courses in dogs with tumors. Overall survival time (OST) analysis was performed in 195 dogs with tumors, stratified with a recommended cut-off (1.514 µg/mL). Continual DR-70 measurements were performed during the medical interventions of 27 dogs with neoplasms. Clinical conditions and medical records were retrospectively reviewed. According to a cut-off value, dogs with plasma DR-70 concentrations above 1.514 µg/mL had shorter survival rates than those with concentrations below this threshold. In cases with complete or partial remission in response to treatment, the DR-70 concentration was decreased compared with that at the first visit, whereas it was increased in patients with disease progression. Our study suggested that changes in DR-70 concentration can be used as a prognostic biomarker for canine neoplasms. Furthermore, increased plasma DR-70 levels might be associated with shorter survival, and DR-70 concentrations may reflect responses to medical intervention.

References

Manuali E, De Giuseppe A, Feliziani F, Forti K, Casciari C, Marchesi M . CA 15-3 cell lines and tissue expression in canine mammary cancer and the correlation between serum levels and tumour histological grade. BMC Vet Res. 2012; 8:86. PMC: 3412725. DOI: 10.1186/1746-6148-8-86. View

Valencakova-Agyagosova A, Frischova Z, Sevcikova Z, Hajurka J, Lepej J, Szakallova I . Determination of carcinoembryonic antigen and cancer antigen (CA 15-3) in bitches with tumours on mammary gland: preliminary report. Vet Comp Oncol. 2012; 12(3):205-14. DOI: 10.1111/j.1476-5829.2012.00353.x. View

Senhorello I, Terra E, R Sueiro F, Firmo B, Anai L, Goloni C . Clinical value of carcinoembryonic antigen in mammary neoplasms of bitches. Vet Comp Oncol. 2019; 18(3):315-323. DOI: 10.1111/vco.12552. View

Duffy M . Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract. 2012; 22(1):4-11. PMC: 5586699. DOI: 10.1159/000338393. View

Rizzo K, Vella K, Zammit D, Gatt P, Grima C, Borg Inguanez M . Fibrinogen measurement in liver disease: validation of the functional fibrinogen thromboelastography assay and a novel mathematical predictive model. Blood Transfus. 2018; 17(3):237-246. PMC: 6596371. DOI: 10.2450/2018.0105-18. View

So H, Hong S, Lee J, Chang Y, Kang S, Hong Y . Comparison of the serum fibrin-fibrinogen degradation products with cytokeratin 19 fragment as biomarkers in patients with lung cancer. Biomed Rep. 2014; 2(5):737-742. PMC: 4106540. DOI: 10.3892/br.2014.315. View

Moik F, Ay C . Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer. J Thromb Haemost. 2022; 20(12):2733-2745. PMC: 9827869. DOI: 10.1111/jth.15880. View

Hung Y, Chen M, Lin J, Hsiao C, Shan Y, Chen Y . The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients. J Chin Med Assoc. 2018; 81(7):593-598. DOI: 10.1016/j.jcma.2018.01.009. View

Repetto O, De Re V . Coagulation and fibrinolysis in gastric cancer. Ann N Y Acad Sci. 2017; 1404(1):27-48. DOI: 10.1111/nyas.13454. View

10.

Prouteau A, Denis J, De Fornel P, Cadieu E, Derrien T, Kergal C . Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma. Sci Rep. 2021; 11(1):877. PMC: 7806858. DOI: 10.1038/s41598-020-80332-y. View

11.

Li X, Qiao Z, Long X, Wei J, Cheng Y . Serum concentration of AMDL DR-70 for the diagnosis and prognosis of carcinoma of the tongue. Br J Oral Maxillofac Surg. 2005; 43(6):513-5. DOI: 10.1016/j.bjoms.2004.11.020. View

12.

Heishima K, Ichikawa Y, Yoshida K, Iwasaki R, Sakai H, Nakagawa T . Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease. Sci Rep. 2017; 7(1):2301. PMC: 5442106. DOI: 10.1038/s41598-017-02607-1. View

13.

Yesil A, Abanonu G, Colak Y, Paker N, Gonen C . Prognostic Significance of DR-70 Levels in Dysplastic Colorectal Polyps. Gastroenterol Res Pract. 2013; 2013:275392. PMC: 3857898. DOI: 10.1155/2013/275392. View

14.

Filippsen Favaro P, Stewart S, McDonald B, Cawley J, Contente-Cuomo T, Wong S . Feasibility of circulating tumor DNA analysis in dogs with naturally occurring malignant and benign splenic lesions. Sci Rep. 2022; 12(1):6337. PMC: 9012871. DOI: 10.1038/s41598-022-09716-6. View

15.

Adam S, Key N, Greenberg C . D-dimer antigen: current concepts and future prospects. Blood. 2008; 113(13):2878-87. DOI: 10.1182/blood-2008-06-165845. View

16.

Beffagna G, Sammarco A, Bedin C, Romualdi C, Mainenti M, Mollo A . Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index. PLoS One. 2017; 12(1):e0169454. PMC: 5231265. DOI: 10.1371/journal.pone.0169454. View

17.

Faria S, Sagebiel T, Patnana M, Cox V, Viswanathan C, Lall C . Tumor markers: myths and facts unfolded. Abdom Radiol (NY). 2018; 44(4):1575-1600. DOI: 10.1007/s00261-018-1845-0. View

18.

Thachil J, Lippi G, Favaloro E . D-Dimer Testing: Laboratory Aspects and Current Issues. Methods Mol Biol. 2017; 1646:91-104. DOI: 10.1007/978-1-4939-7196-1_7. View

19.

Fan Y, Ren X, Liu X, Shi D, Xu E, Wang S . Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients. Sci Rep. 2021; 11(1):6651. PMC: 7988110. DOI: 10.1038/s41598-021-85029-4. View

20.

Ke C, Sio K, Wu C, Xia Y, Lee J, Hu C . Increased plasma DR-70 (fibrinogen-fibrin degradation products) concentrations as a diagnostic biomarker in dogs with neoplasms. J Vet Intern Med. 2023; 37(6):2391-2401. PMC: 10658483. DOI: 10.1111/jvim.16898. View